OMEROS CORP

Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule and protein therapeutics for immunologic and orphan diseases. The company's most advanced program is narsoplimab (OMS721/MASP-2), a complement inhibitor targeting hematopoietic stem-cell transplant-associated thrombotic microangiopathy, with additional Phase II development in COVID-19 and acute respiratory distress syndrome. Zaltenibart, another key candidate, is in Phase 3 trials for paroxysmal nocturnal hemoglobinuria and Phase 2 development for complement 3 glomerulopathy and alternative pathway disorders.

The company's pipeline includes OMS1029 for MASP-2 and lectin pathway disorders (completed Phase I), OMS527 for addiction, compulsive disorders, and movement disorders including cocaine use disorder (Phase I), and multiple programs in preclinical development targeting complement pathway regulation and oncology indications. Development focuses on lectin and alternative complement pathway modulation as well as adoptive T-cell and cancer immunotherapy approaches.

Based in Seattle, Washington, Omeros operates with approximately 202 full-time employees. The company is incorporated in Washington and trades on the Nasdaq. As a clinical-stage enterprise, the company does not currently generate product revenues and remains dependent on capital resources and potential milestone payments for financial sustainability.